In Silico Molecular Docking Analysis of Karanjin against Alzheimer's and Parkinson's Diseases as a Potential Natural Lead Molecule for New Drug Design, Development and Therapy.
Parkinson's disease (PD) and Alzheimer's disease (AD) are neurodegenerative disorders that have emerged as among the serious health problems of the 21st century. The medications currently available to treat AD and PD have limited efficacy and are associated with side effects. Natural produ...
Published in: | Molecules |
---|---|
Main Authors: | , , , , , , , , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
MDPI
2022
|
Subjects: | |
Online Access: | https://doi.org/10.3390/molecules27092834 https://pubmed.ncbi.nlm.nih.gov/35566187 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100660/ |
id |
ftpubmed:35566187 |
---|---|
record_format |
openpolar |
spelling |
ftpubmed:35566187 2024-09-09T20:02:25+00:00 In Silico Molecular Docking Analysis of Karanjin against Alzheimer's and Parkinson's Diseases as a Potential Natural Lead Molecule for New Drug Design, Development and Therapy. Gnanaraj, Charles Sekar, Mahendran Fuloria, Shivkanya Swain, Shasank S Gan, Siew Hua Chidambaram, Kumarappan Rani, Nur Najihah Izzati Mat Balan, Tavamani Stephenie, Sarah Lum, Pei Teng Jeyabalan, Srikanth Begum, M Yasmin Chandramohan, Vivek Thangavelu, Lakshmi Subramaniyan, Vetriselvan Fuloria, Neeraj Kumar 2022 Apr 29 https://doi.org/10.3390/molecules27092834 https://pubmed.ncbi.nlm.nih.gov/35566187 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100660/ eng eng MDPI https://doi.org/10.3390/molecules27092834 https://pubmed.ncbi.nlm.nih.gov/35566187 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100660/ Molecules ISSN:1420-3049 Volume:27 Issue:9 ADMET Alzheimer’s disease Lipinski’s rule Parkinson’s disease bioinformatics drug-likeness in silico karanjin molecular dynamics Journal Article 2022 ftpubmed https://doi.org/10.3390/molecules27092834 2024-08-27T16:03:00Z Parkinson's disease (PD) and Alzheimer's disease (AD) are neurodegenerative disorders that have emerged as among the serious health problems of the 21st century. The medications currently available to treat AD and PD have limited efficacy and are associated with side effects. Natural products are one of the most vital and conservative sources of medicines for treating neurological problems. Karanjin is a furanoflavonoid, isolated mainly from Pongamia pinnata with several medicinal plants, and has been reported for numerous health benefits. However, the effect of karanjin on AD and PD has not yet been systematically investigated. To evaluate the neuroprotective effect of karanjin, extensive in silico studies starting with molecular docking against five putative targets for AD and four targets for PD were conducted. The findings were compared with three standard drugs using Auto Dock 4.1 and Molegro Virtual Docker software. Additionally, the physiochemical properties (Lipinski rule of five), drug-likeness and parameters including absorption, distribution, metabolism, elimination and toxicity (ADMET) profiles of karanjin were also studied. The molecular dynamics (MD) simulations were performed with two selective karanjin docking complexes to analyze the dynamic behaviors and binding free energy at 100 ns time scale. In addition, frontier molecular orbitals (FMOs) and density-functional theory (DFT) were also investigated from computational quantum mechanism perspectives using the Avogadro-ORCA 1.2.0 platform. Karanjin complies with all five of Lipinski's drug-likeness rules with suitable ADMET profiles for therapeutic use. The docking scores (kcal/mol) showed comparatively higher potency against AD and PD associated targets than currently used standard drugs. Overall, the potential binding affinity from molecular docking, static thermodynamics feature from MD-simulation and other multiparametric drug-ability profiles suggest that karanjin could be considered as a suitable therapeutic lead for AD and PD treatment. Furthermore, the present results were strongly correlated with the earlier study on karanjin in an Alzheimer's animal model. However, necessary in vivo studies, clinical trials, bioavailability, permeability and safe dose administration, etc. must be required to use karanjin as a potential drug against AD and PD treatment, where the in silico results are more helpful to accelerate the drug development. Article in Journal/Newspaper Orca PubMed Central (PMC) Molecules 27 9 2834 |
institution |
Open Polar |
collection |
PubMed Central (PMC) |
op_collection_id |
ftpubmed |
language |
English |
topic |
ADMET Alzheimer’s disease Lipinski’s rule Parkinson’s disease bioinformatics drug-likeness in silico karanjin molecular dynamics |
spellingShingle |
ADMET Alzheimer’s disease Lipinski’s rule Parkinson’s disease bioinformatics drug-likeness in silico karanjin molecular dynamics Gnanaraj, Charles Sekar, Mahendran Fuloria, Shivkanya Swain, Shasank S Gan, Siew Hua Chidambaram, Kumarappan Rani, Nur Najihah Izzati Mat Balan, Tavamani Stephenie, Sarah Lum, Pei Teng Jeyabalan, Srikanth Begum, M Yasmin Chandramohan, Vivek Thangavelu, Lakshmi Subramaniyan, Vetriselvan Fuloria, Neeraj Kumar In Silico Molecular Docking Analysis of Karanjin against Alzheimer's and Parkinson's Diseases as a Potential Natural Lead Molecule for New Drug Design, Development and Therapy. |
topic_facet |
ADMET Alzheimer’s disease Lipinski’s rule Parkinson’s disease bioinformatics drug-likeness in silico karanjin molecular dynamics |
description |
Parkinson's disease (PD) and Alzheimer's disease (AD) are neurodegenerative disorders that have emerged as among the serious health problems of the 21st century. The medications currently available to treat AD and PD have limited efficacy and are associated with side effects. Natural products are one of the most vital and conservative sources of medicines for treating neurological problems. Karanjin is a furanoflavonoid, isolated mainly from Pongamia pinnata with several medicinal plants, and has been reported for numerous health benefits. However, the effect of karanjin on AD and PD has not yet been systematically investigated. To evaluate the neuroprotective effect of karanjin, extensive in silico studies starting with molecular docking against five putative targets for AD and four targets for PD were conducted. The findings were compared with three standard drugs using Auto Dock 4.1 and Molegro Virtual Docker software. Additionally, the physiochemical properties (Lipinski rule of five), drug-likeness and parameters including absorption, distribution, metabolism, elimination and toxicity (ADMET) profiles of karanjin were also studied. The molecular dynamics (MD) simulations were performed with two selective karanjin docking complexes to analyze the dynamic behaviors and binding free energy at 100 ns time scale. In addition, frontier molecular orbitals (FMOs) and density-functional theory (DFT) were also investigated from computational quantum mechanism perspectives using the Avogadro-ORCA 1.2.0 platform. Karanjin complies with all five of Lipinski's drug-likeness rules with suitable ADMET profiles for therapeutic use. The docking scores (kcal/mol) showed comparatively higher potency against AD and PD associated targets than currently used standard drugs. Overall, the potential binding affinity from molecular docking, static thermodynamics feature from MD-simulation and other multiparametric drug-ability profiles suggest that karanjin could be considered as a suitable therapeutic lead for AD and PD treatment. Furthermore, the present results were strongly correlated with the earlier study on karanjin in an Alzheimer's animal model. However, necessary in vivo studies, clinical trials, bioavailability, permeability and safe dose administration, etc. must be required to use karanjin as a potential drug against AD and PD treatment, where the in silico results are more helpful to accelerate the drug development. |
format |
Article in Journal/Newspaper |
author |
Gnanaraj, Charles Sekar, Mahendran Fuloria, Shivkanya Swain, Shasank S Gan, Siew Hua Chidambaram, Kumarappan Rani, Nur Najihah Izzati Mat Balan, Tavamani Stephenie, Sarah Lum, Pei Teng Jeyabalan, Srikanth Begum, M Yasmin Chandramohan, Vivek Thangavelu, Lakshmi Subramaniyan, Vetriselvan Fuloria, Neeraj Kumar |
author_facet |
Gnanaraj, Charles Sekar, Mahendran Fuloria, Shivkanya Swain, Shasank S Gan, Siew Hua Chidambaram, Kumarappan Rani, Nur Najihah Izzati Mat Balan, Tavamani Stephenie, Sarah Lum, Pei Teng Jeyabalan, Srikanth Begum, M Yasmin Chandramohan, Vivek Thangavelu, Lakshmi Subramaniyan, Vetriselvan Fuloria, Neeraj Kumar |
author_sort |
Gnanaraj, Charles |
title |
In Silico Molecular Docking Analysis of Karanjin against Alzheimer's and Parkinson's Diseases as a Potential Natural Lead Molecule for New Drug Design, Development and Therapy. |
title_short |
In Silico Molecular Docking Analysis of Karanjin against Alzheimer's and Parkinson's Diseases as a Potential Natural Lead Molecule for New Drug Design, Development and Therapy. |
title_full |
In Silico Molecular Docking Analysis of Karanjin against Alzheimer's and Parkinson's Diseases as a Potential Natural Lead Molecule for New Drug Design, Development and Therapy. |
title_fullStr |
In Silico Molecular Docking Analysis of Karanjin against Alzheimer's and Parkinson's Diseases as a Potential Natural Lead Molecule for New Drug Design, Development and Therapy. |
title_full_unstemmed |
In Silico Molecular Docking Analysis of Karanjin against Alzheimer's and Parkinson's Diseases as a Potential Natural Lead Molecule for New Drug Design, Development and Therapy. |
title_sort |
in silico molecular docking analysis of karanjin against alzheimer's and parkinson's diseases as a potential natural lead molecule for new drug design, development and therapy. |
publisher |
MDPI |
publishDate |
2022 |
url |
https://doi.org/10.3390/molecules27092834 https://pubmed.ncbi.nlm.nih.gov/35566187 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100660/ |
genre |
Orca |
genre_facet |
Orca |
op_source |
Molecules ISSN:1420-3049 Volume:27 Issue:9 |
op_relation |
https://doi.org/10.3390/molecules27092834 https://pubmed.ncbi.nlm.nih.gov/35566187 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100660/ |
op_doi |
https://doi.org/10.3390/molecules27092834 |
container_title |
Molecules |
container_volume |
27 |
container_issue |
9 |
container_start_page |
2834 |
_version_ |
1809934380666191872 |